SKI-349, a Sphingosine Kinases 1/2 Inhibitor, Suppresses Cell Viability, Invasion, and AKT/mTOR Signaling Pathway, and Shows Synergistic Cytotoxic Effects with Sorafenib in Hepatocellular Carcinoma

Tohoku J Exp Med. 2023 Dec 21. doi: 10.1620/tjem.2023.J100. Online ahead of print.NO ABSTRACTPMID:38123304 | DOI:10.1620/tjem.2023.J100

Source: The Tohoku Journal of Experimental Medicine - December 20, 2023 Category: Research Authors: Liqiao Chen Liangliang Wang Zongqi Han Peng Qin Guangxu Niu Jingxia Du Source Type: research